SALT LAKE CITY–Idaho Technology, Inc. has signed a licensing agreement with Finnzymes Oy, covering reagents or methods using SYBR® Green I technology and melting curve analysis for real time PCR.

This extends Idaho Technology’s ongoing program to license its broad and valuable intellectual property portfolio in cooperation with Roche Diagnostics GmbH. The agreement, effective April 3, 2009, follows a series of intellectual property licensing agreements with a number of other biotechnology companies over the last several years.

Idaho Technlogy’s SYBR intellectual property has been useful expanding applications in molecular biology with the use of real time PCR products.

About Idaho Technology

Idaho Technology, Inc. is a privately held biotechnology company based in Salt Lake City, Utah. Founded in 1990, Idaho Technology licensed the rapid PCR technology from the University of Utah. Through funds from the United States Department of Health and Human Services and the Department of Defense, the company has created many commercial instruments and reagents for use in research and applied fields. Several of these products, including the LightCycler® Instrument, have been sublicensed to Roche Diagnostics. Researchers, medical technicians, law enforcement officers, and soldiers in the field use the company’s devices to detect or study disease-causing organisms. For further information, please visit www.idahotech.com.

About Finnzymes

Finnzymes Oy is a Finnish biotechnology company founded in 1986. The company focuses on development of PCR, qPCR, transposon, RNA, and nucleic acid based diagnostics technologies. Finnzymes offers a wide range of proprietary technologies including Phusion® High-Fidelity DNA Polymerases, Piko® Thermal Cyclers and UTW® reaction vessels. The company has also pioneered the field of Direct PCR eliminating the need for DNA purification. Finnzymes’ key customers include academic and industrial laboratories, hospitals and government agencies. For further information, please visit www.finnzymes.com.